Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. announced that its Phase IIb study results for MRG003, an innovative ADC targeting EGFR for recurrent or metastatic nasopharyngeal cancer, have been selected for oral presentation at the 2025 ASCO Annual Meeting. This recognition highlights the potential impact of MRG003 in cancer treatment, although the company cautions that successful development and marketing are not guaranteed, advising shareholders and investors to exercise caution.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative antibody drug conjugates (ADCs) targeting various cancers. The company is involved in creating treatments for conditions such as nasopharyngeal cancer, leveraging its expertise in targeting epidermal growth factor receptors (EGFR) which are prevalent in several malignant tumors.
YTD Price Performance: 19.47%
Average Trading Volume: 8,579,545
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.35B
For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.